Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Engelhardt
J Finke

Blood

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Blood|July 27, 2001
Does telomere shortening count?M Engelhardt, J Finke
Blood|December 4, 2010
IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasmsKais Hussein, Bianca M Engelhardt, Hans Kreipe, et al.
Blood|July 1, 1997
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cellsM Engelhardt, R Kumar, J Albanell, et al.
Blood|October 1, 1996
Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cellsR M Weber-Nordt, R Henschler, E Schott, et al.
Blood|July 15, 1992
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genesJ Finke, R Fritzen, P Ternes, et al.
Blood|August 1, 1996
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell linesR M Weber-Nordt, C Egen, J Wehinger, et al.
Blood|March 26, 1999
Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathwayV Kolenko, P Rayman, B Roy, et al.
Blood|August 8, 1998
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalphaW Ling, P Rayman, R Uzzo, et al.
Blood|December 1, 1995
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrowD von Laer, U Meyer-Koenig, A Serr, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Blood|July 27, 2001
Does telomere shortening count?M Engelhardt, J Finke
Blood|December 4, 2010
IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasmsKais Hussein, Bianca M Engelhardt, Hans Kreipe, et al.
Blood|July 1, 1997
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cellsM Engelhardt, R Kumar, J Albanell, et al.
Blood|October 1, 1996
Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cellsR M Weber-Nordt, R Henschler, E Schott, et al.
Blood|July 15, 1992
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genesJ Finke, R Fritzen, P Ternes, et al.
Blood|August 1, 1996
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell linesR M Weber-Nordt, C Egen, J Wehinger, et al.
Blood|March 26, 1999
Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathwayV Kolenko, P Rayman, B Roy, et al.
Blood|August 8, 1998
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalphaW Ling, P Rayman, R Uzzo, et al.
Blood|December 1, 1995
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrowD von Laer, U Meyer-Koenig, A Serr, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Pageof 1